CXCL3 and cholangiocarcinoma: Subimerb et al found that in cholangiocarcinoma patients, the peripheral CD16+ monocytes had tumor-promoting characteristics and expressed higher levels of growth factor (EREG) and angiogenic chemokines (CXCL3), these cytokines corresponded to a M2 pro-tumorigenic phenotype [34].